Nuage Therapeutics — Seed (estimated) · €1.8M

Nuage Therapeutics received a €1.8M equity injection from CDTI Innovación's Innvierte programme and Sofinnova Capital X to take its first oncology drug candidate (against intrinsically disordered proteins) through preclinical development. With this deal, CDTI's total commitment to the company is close to €3M. No lead was named. The €2.7M the company received in December 2025 from the Spanish State Research Agency (AEI) was a public R&D grant, not a funding round, so it is excluded.